ANTIVIRAL DRUGS ADVISORY COMMITTEE
January 10, 2001
NDA 21-227 Cancidas (caspofungin) Injection
(Proposed for the treatment of invasive aspergillosis in patients who are
refractory to or intolerant of other therapies)
BRIEFING INFORMATION
Merck Research Laboratories
Disclaimer
The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Briefing Information pdf